ORIGINAL RESEARCH article

Front. Mol. Biosci.

Sec. Molecular Diagnostics and Therapeutics

Volume 12 - 2025 | doi: 10.3389/fmolb.2025.1621398

This article is part of the Research TopicExploring the Correlation and Heterogeneity Between Acute and Chronic Diseases: Diagnostic and Therapeutic PerspectivesView all 4 articles

Mechanism of Shi-Yang-Xiao Lotion in Alleviating Perianal Eczema based on Network Pharmacology and Experimental Validation

Provisionally accepted
Zhimin FanZhimin Fan1*Chuyue HuangChuyue Huang1Bingwen ZhouBingwen Zhou1Meng DuanMeng Duan1Tuotuo ZhengTuotuo Zheng2Yan TangYan Tang3Qingrui LiuQingrui Liu1Yujing DongYujing Dong4Desong KongDesong Kong1Qiang LengQiang Leng1Lu WangLu Wang1
  • 1Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China
  • 2Xuzhou city Hospital of Traditional Chinese Medicine, xuzhou, China
  • 3Chongqing Banan Hospital of Traditional Chinese Medicin, chongqing, China
  • 4Nantong Hospital Affiliated to Nanjing University of Chinese Medicine, nantong, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Background: Shi-Yang-Xiao lotion (SYXL), due to its anti-inflammatory and antipruritic properties, is widely used in treating Perianal Eczema (PE) with remarkable clinical efficacy. However, the chemical constituents of SYXL and its underlying mechanisms of action in treating PE remain to be elucidated. Aim of the study: To elucidate the molecular mechanisms underlying the therapeutic efficacy of SYXL in treating PE by integrating network pharmacology techniques with experimental validation. Materials and methods: Ultra Performance Liquid Chromatography-Quadrupole Time-Of-Flight-Mass Spectrometry/Mass Spectrometry (UPLC-QTOF-MS/MS) was utilized to identify the effective chemical constituents of SYXL. Potential targets and pathways were elucidated utilizing network pharmacology analysis. Subsequently, ELISA and western blotting were utilized in a rat model of PE induced by DNCB, and in HaCaT cells co-stimulated with tumor necrosis factor-α (TNF-α) and interferon-γ for further validation. Results: UPLC-QTOF-MS/MS identified a total of 93 compounds. Network pharmacology analysis revealed that the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway was predicted to play major roles in the therapeutic effects of SYXL on PE. In vivo experiments demonstrated that SYXL ameliorated eczema-like skin lesions. Both in vivo and in vitro, SYXL inhibited the production of inflammatory cytokines, suppressed the phosphorylation of JAK2 and STAT3, thereby blocking the JAK-STAT signaling pathway. Conclusion: Our findings indicated that SYXL repaired skin barrier, suppressed inflammation, and treated PE by decreasing the generation of interleukin-1β, interleukin-6, and TNF-α, as well as inhibiting the phosphorylation of JAK2 and STAT3.

Keywords: Perianal eczema, Shi-Yang-Xiao lotion, Network Pharmacology, Traditional Chinese Medicine, JAK2-STAT3 pathway

Received: 01 May 2025; Accepted: 27 May 2025.

Copyright: © 2025 Fan, Huang, Zhou, Duan, Zheng, Tang, Liu, Dong, Kong, Leng and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Zhimin Fan, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material